Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results, Beats Estimates By $0.02 EPS

Lifecore Biomedical (NASDAQ:LFCR) posted its quarterly earnings results on Thursday. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%.

Lifecore Biomedical Trading Up 14.4 %

Shares of Lifecore Biomedical stock opened at $7.62 on Friday. The firm has a 50-day simple moving average of $7.03 and a two-hundred day simple moving average of $5.79. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. Lifecore Biomedical has a fifty-two week low of $3.68 and a fifty-two week high of $8.90. The company has a market cap of $280.62 million, a P/E ratio of 95.25 and a beta of 0.98.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on LFCR shares. Craig Hallum boosted their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd. Stephens reissued an “equal weight” rating and issued a $6.00 price target on shares of Lifecore Biomedical in a report on Friday.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.